SCHEMBL4999345

SCHEMBL4999345

Cc1ccc(/C(N)=C2/C(=O)Nc3ccccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.52
▸ IDO1 P14902 3/20 0.50
▸ TDO2 P48775 1/20 0.50
▸ CSNK1G1 Q9HCP0 1/20 0.48
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ ACVR1 Q04771 2/20 0.46
▸ LRRK2 Q5S007 2/20 0.46
▸ ROS1 P08922 1/20 0.46
▸ CDK5 Q00535 1/20 0.46
▸ PDGFRA P16234 1/20 0.43
▸ FER P16591 1/20 0.43
▸ LTK P29376 1/20 0.43
▸ CDK8 P49336 1/20 0.43
▸ DYRK1B Q9Y463 1/20 0.43
▸ MAPT P10636 4/20 0.42
▸ LMNA P02545 2/20 0.42
▸ AGTR1 P30556 1/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2829329 0.87 TDP1 (0.50) TDP1IDO1TDO2MAOAMAOB
SCHEMBL2829327 0.87 TDP1 (0.50) TDP1IDO1TDO2MAOAMAOB
SCHEMBL13207305 0.86 PLK4 (0.50) TDP1IDO1TDO2MAOAMAOB
SCHEMBL2826123 0.86 PLK4 (0.50) TDP1IDO1TDO2MAOAMAOB
SCHEMBL2826121 0.86 PLK4 (0.50) TDP1IDO1TDO2MAOAMAOB
SCHEMBL13207359 0.85 TDP1 (0.49) TDP1IDO1TDO2MAOAMAOB
SCHEMBL13207307 0.85 TDP1 (0.49) TDP1IDO1TDO2MAOAMAOB
SCHEMBL2829139 0.85 TDP1 (0.49) TDP1IDO1TDO2MAOAMAOB
SCHEMBL2829197 0.85 TDP1 (0.49) TDP1IDO1TDO2MAOAMAOB
SCHEMBL2829194 0.85 TDP1 (0.49) TDP1IDO1TDO2MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 — — US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 — — US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 — — US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 — — US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 — — US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 — — US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 — — US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 — — US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 — — US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 — — US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 TDP1 1661/4885IDO1 404/4885TDO2 806/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 TDP1 1661/4885IDO1 404/4885TDO2 806/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 TDP1 1661/4885IDO1 404/4885TDO2 806/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 TDP1 1661/4885IDO1 404/4885TDO2 806/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 TDP1 1661/4885IDO1 404/4885TDO2 806/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 TDP1 1661/4885IDO1 404/4885TDO2 806/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 TDP1 1661/4885IDO1 404/4885TDO2 806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback